| FAK Inhibitor in Patients With Advanced Solid Tumors (NCT07596381) | InxMed (Shanghai) Co., Ltd. | 2026-05-30 |
| IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors (NCT07441174) | InxMed (Shanghai) Co., Ltd. | 2026-02-28 |
| A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (NCT07174908) | InxMed (Shanghai) Co., Ltd. | 2025-09-10 |
| IN10018 Combination Therapy in Previously-treated Solid Tumors (NCT05982522) | InxMed (Shanghai) Co., Ltd. | 2025-08-13 |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC (NCT06030258) | InxMed (Shanghai) Co., Ltd. | 2023-10-30 |
| IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC (NCT05994131) | InxMed (Shanghai) Co., Ltd. | 2023-07-13 |
| IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer (NCT05827796) | InxMed (Shanghai) Co., Ltd. | 2022-12-08 |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528) | InxMed (Shanghai) Co., Ltd. | 2022-09-06 |
| IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients (NCT05830539) | InxMed (Shanghai) Co., Ltd. | 2022-03-10 |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer (NCT05551507) | InxMed (Shanghai) Co., Ltd. | 2020-07-27 |
| IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma (NCT05327231) | InxMed (Shanghai) Co., Ltd. | 2020-07-09 |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (NCT04109456) | InxMed (Shanghai) Co., Ltd. | 2020-03-16 |